Saudi Arabia has temporarily closed its East-West oil pipeline, which transports about 4 million barrels per day, due to drone attacks. This closure forces more crude exports through the vulnerable Strait of Hormuz, tightening global oil supply amid ongoing Middle East conflicts. With global oil inventories already down by around 1 billion barrels, analysts warn that if the pipeline remains offline beyond a five-to-seven-day inventory cushion, oil prices could surge sharply above $100 per barrel. Repair timelines remain uncertain, and regional tensions continue to threaten oil export routes, raising concerns over prolonged supply disruptions and higher energy costs worldwide.
Saudi Arabia's oil pipeline closure is the story's subject. For readers following energy markets, here is Pluang's market snapshot as of Sep 15, 2026 15:51 WIB: Of 30 priced Energy-sector US stocks tradable on Pluang, 19 rose and 9 fell today. Notable prices include EOSE at USD 3.78 (-1.05%), INDO at USD 3.10 (+0.98%), and COP at USD 137.96 (+0.94%).
At ESMO 2026, Roche presented key Phase III trial results showcasing significant advances in cancer treatment. Divarasib demonstrated superior efficacy over first-generation KRAS G12C inhibitors in advanced lung cancer, potentially setting a new stan...
Red Cat Holdings announced a voluntary public purchase offer to acquire all outstanding shares of Steyr Motors AG at €39 per share in cash, representing a significant premium over recent prices. The acquisition aims to strengthen Red Cat's Blue Ops u...
Hayati®, a UK-based technology and vaping brand, partnered with elrow at the Edinburgh Festival to launch the "TURN UP WITH HAYATI®" activation. This collaboration featured a dedicated space with interactive activities, special festival edition produ...
Wormhole (W) has fallen about 10% recently, driven mainly by large investors (whales) selling on OKX, while Binance whales are accumulating. The Funding Rate shows reduced bearish pressure, improving from -0.0484% to -0.0083%, indicating a gradual bu...
Zealand Pharma announced positive topline results from the multiple ascending dose part of its Phase 1 trial for ZP9830, a novel Kv1.3 ion channel blocker targeting autoimmune diseases. The drug was well tolerated with no serious adverse events in 32...
